COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA

PURPOSE: To examine the impact of initiating fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in a single device on chronic obstructive pulmonary disease (COPD) exacerbations, COPD exacerbation-related costs, and all-cause and COPD-related healthcare resource utilization (HCRU) and costs in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanania, Nicola A, Bunner, Scott H, Bengtson, Lindsay G S, Ismaila, Afisi S, Bogart, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045302/
https://www.ncbi.nlm.nih.gov/pubmed/36998390
http://dx.doi.org/10.2147/COPD.S378867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045302/
https://www.ncbi.nlm.nih.gov/pubmed/36998390
http://dx.doi.org/10.2147/COPD.S378867

Ejemplares similares